STOCK TITAN

Brii Biosciences Limited - BRIBY STOCK NEWS

Welcome to our dedicated news page for Brii Biosciences (Ticker: BRIBY), a resource for investors and traders seeking the latest updates and insights on Brii Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Brii Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Brii Biosciences's position in the market.

Rhea-AI Summary
Brii Biosciences Limited acquires all intellectual properties related to BRII-179, eliminates future milestone and royalty payments to VBI, and secures rights to VBI-1901 APAC, expanding global commercial supplies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags
-
Rhea-AI Summary
Brii Biosciences Limited (2137.HK) appoints Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, bringing extensive experience in medicine discovery and development from big pharma and start-up biotech companies. Dr. Johns will lead the discovery programs and set the future pipeline strategy at Brii Bio, focusing on transformative therapies against infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Brii Biosciences Limited (2137.HK) shared new data at the AASLD The Liver Meeting® in Boston, MA, demonstrating the potential of BRII-179 to improve HBsAg loss and HBV functional cure rates. The data support progression to late-stage clinical development, aiming to inform curative treatment approaches in chronic Hepatitis B.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Brii Bio announces positive results for BRII-179 in Phase 2 study for chronic hepatitis B
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Brii Biosciences reports positive interim results and updates on its therapies for HBV and PPD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Brii Biosciences has announced the dosing of the first subject in a Phase 1 clinical trial for BRII-297, a long-acting injectable treatment for anxiety and depressive disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Brii Biosciences Limited

OTC:BRIBY

BRIBY Rankings

BRIBY Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services